;PMID: 11199127 ;source_file_1909.mrg ;Release 0.9 of PennBioIE ;Funded by NSF ITR EIA-0205448 ;0)section:[e:0..33] = [t:0..33] ;1)sentence:[e:39..176] = [t:39..176] ;2)section:[e:180..276] = [t:180..276] ;3)section:[e:280..375] = [t:280..375] ;4)sentence:[e:379..558] = [t:379..558] ;5)sentence:[e:559..710] = [t:559..710] ;6)sentence:[e:711..826] = [t:711..826] ;7)sentence:[e:827..1002] = [t:827..1002] ;8)sentence:[e:1003..1182] = [t:1003..1182] ;9)sentence:[e:1183..1285] = [t:1183..1285] ;10)sentence:[e:1286..1441] = [t:1286..1441] ;11)section:[e:1445..1490] = [t:1445..1490] ;section 0 Span:0..33 ;Planta Med. 2000 Dec;66(8):714-9. (SEC (FRAG (NNP:[0..6] Planta) (NNP:[7..10] Med) (.:[10..11] .) (CD:[12..16] 2000) (CC:[17..24] Dec;66-LRB-) (CD:[24..25] 8) (-RRB-:[25..26] -RRB-) (::[26..27] :) (CD:[27..30] 714) (::[30..31] -) (CD:[31..33] 9.))) ;sentence 1 Span:39..176 ;Panax vietnamensis protects mice against carbon tetrachloride-induced ;hepatotoxicity without any modification of CYP2E1 gene expression. ;[39..57]:substance:"Panax vietnamensis" ;[80..100]:substance:"carbon tetrachloride" (SENT (S-HLN (NP-SBJ (NN:[39..44] Panax) (NN:[45..57] vietnamensis)) (VP (NNS:[58..66] protects) (NP (NNS:[67..71] mice)) (PP-CLR (IN:[72..79] against) (NP (ADJP (NML (NN:[80..86] carbon) (NN:[87..100] tetrachloride)) (HYPH:[100..101] -) (VBN:[101..108] induced)) (NN:[110..124] hepatotoxicity))) (PP (IN:[125..132] without) (NP (NP (DT:[133..136] any) (NN:[137..149] modification)) (PP (IN:[150..152] of) (NP (NN:[153..159] CYP2E1) (NN:[160..164] gene) (NN:[165..175] expression)))))) (.:[175..176] .))) ;section 2 Span:180..276 ;Nguyen TD, Villard PH, Barlatier A, Elsisi AE, Jouve E, Duc NM, Sauze C, ;Durand A, Lacarelle B. (SEC (FRAG (NNP:[180..186] Nguyen) (NN:[187..189] TD) (,:[189..190] ,) (NNP:[191..198] Villard) (NNP:[199..201] PH) (,:[201..202] ,) (NNP:[203..212] Barlatier) (NNP:[213..214] A) (,:[214..215] ,) (NNP:[216..222] Elsisi) (NNP:[223..225] AE) (,:[225..226] ,) (NNP:[227..232] Jouve) (NNP:[233..234] E) (,:[234..235] ,) (NNP:[236..239] Duc) (NNP:[240..242] NM) (,:[242..243] ,) (NNP:[244..249] Sauze) (NNP:[250..251] C) (,:[251..252] ,) (NNP:[253..259] Durand) (NNP:[261..262] A) (,:[262..263] ,) (NNP:[264..273] Lacarelle) (NNP:[274..276] B.))) ;section 3 Span:280..375 ;Laboratory of Toxicology (EA2194), School of Pharmacy, Univ. Mediterranee, ;Marseilles, France. (SEC (FRAG (NNP:[280..290] Laboratory) (IN:[291..293] of) (NNP:[294..304] Toxicology) (-LRB-:[305..306] -LRB-) (NN:[306..312] EA2194) (-RRB-:[312..313] -RRB-) (,:[313..314] ,) (NNP:[315..321] School) (IN:[322..324] of) (NNP:[325..333] Pharmacy) (,:[333..334] ,) (NNP:[335..339] Univ) (.:[339..340] .) (NNP:[341..353] Mediterranee) (,:[353..354] ,) (NNP:[356..366] Marseilles) (,:[366..367] ,) (NNP:[368..374] France) (.:[374..375] .))) ;sentence 4 Span:379..558 ;In order to explore the effect of Panax vietnamensis on carbon ;tetrachloride-induced hepatotoxicity, mice were pretreated for 7 days with ;either crude extract or total saponins. ;[413..431]:substance:"Panax vietnamensis" ;[435..456]:substance:"carbon tetrachloride" ;[506..507]:quantitative-value:"7" ;[508..512]:quantitative-units:"days" ;[526..539]:substance:"crude extract" ;[549..557]:substance:"saponins" (SENT (S (SBAR-PRP (IN:[379..381] In) (NN:[382..387] order) (S (NP-SBJ (-NONE-:[387..387] *)) (VP (TO:[388..390] to) (NP (VB:[391..398] explore) (NP (NP (DT:[399..402] the) (NN:[403..409] effect)) (PP (IN:[410..412] of) (NP (NN:[413..418] Panax) (NN:[419..431] vietnamensis)))) (PP (IN:[432..434] on) (NP (ADJP (NML (NN:[435..441] carbon) (NN:[443..456] tetrachloride)) (HYPH:[456..457] -) (VBN:[457..464] induced)) (NN:[465..479] hepatotoxicity))))))) (,:[479..480] ,) (NP-SBJ-1 (NNS:[481..485] mice)) (VP (VBD:[486..490] were) (VP (VBN:[491..501] pretreated) (NP-1 (-NONE-:[501..501] *)) (PP-TMP (IN:[502..505] for) (NP (CD:[506..507] 7) (NNS:[508..512] days))) (PP (IN:[513..517] with) (NP (CC:[519..525] either) (NP (JJ:[526..531] crude) (NN:[532..539] extract)) (CC:[540..542] or) (NP (JJ:[543..548] total) (NNS:[549..557] saponins)))))) (.:[557..558] .))) ;sentence 5 Span:559..710 ;Crude extract and total saponins dramatically decreased carbon ;tetrachloride-induced increase of serum GST alpha level (-50.0%, -49.5% ;respectively). ;[559..572]:substance:"Crude extract" ;[583..591]:substance:"saponins" ;[616..636]:substance:"carbon tetrachloride" ;[663..672]:substance:"GST alpha" ;[681..687]:quantitative-value:"-50.0%" ;[689..695]:quantitative-value:"-49.5%" (SENT (S (NP-SBJ (NP (JJ:[559..564] Crude) (NN:[565..572] extract)) (CC:[573..576] and) (NP (JJ:[577..582] total) (NNS:[583..591] saponins))) (ADVP (RB:[593..605] dramatically)) (VP (VBD:[606..615] decreased) (NP (NP (ADJP (NML (NN:[616..622] carbon) (NN:[623..636] tetrachloride)) (HYPH:[636..637] -) (VBN:[637..644] induced)) (NN:[645..653] increase)) (PP (IN:[654..656] of) (NP (NN:[657..662] serum) (NML (NN:[663..666] GST) (SYM:[667..672] alpha)) (NN:[674..679] level)))) (PRN (-LRB-:[680..681] -LRB-) (FRAG (NP (QP (SYM:[681..682] -) (CD:[682..686] 50.0)) (NN:[686..687] %)) (,:[687..688] ,) (NP (QP (SYM:[689..690] -) (CD:[690..694] 49.5)) (NN:[694..695] %)) (ADVP (RB:[696..708] respectively))) (-RRB-:[708..709] -RRB-))) (.:[709..710] .))) ;sentence 6 Span:711..826 ;Serum AST level was significantly decreased only with total saponins ;(-52.2%) and ALT level was slightly modified. ;[717..720]:substance:"AST" ;[772..780]:substance:"saponins" ;[782..788]:quantitative-value:"-52.2%" ;[794..797]:substance:"ALT" (SENT (S (S (NP-SBJ-2 (NN:[711..716] Serum) (NN:[717..720] AST) (NN:[721..726] level)) (VP (VBD:[727..730] was) (ADVP (RB:[731..744] significantly)) (VP (VBN:[745..754] decreased) (NP-2 (-NONE-:[754..754] *)) (PP (RB:[756..760] only) (IN:[761..765] with) (NP (NP (JJ:[766..771] total) (NNS:[772..780] saponins)) (PRN (-LRB-:[781..782] -LRB-) (NP (QP (SYM:[782..783] -) (CD:[783..787] 52.2)) (NN:[787..788] %)) (-RRB-:[788..789] -RRB-))))))) (CC:[790..793] and) (S (NP-SBJ-1 (NN:[794..797] ALT) (NN:[798..803] level)) (VP (VBD:[804..807] was) (ADVP (RB:[808..816] slightly)) (VP (VBN:[817..825] modified) (NP-1 (-NONE-:[825..825] *))))) (.:[825..826] .))) ;sentence 7 Span:827..1002 ;In vitro experiments shown that both preparations at high concentrations (> ;2000 micrograms/ml) are able to inhibit CYP2E1 enzymatic activity in mouse ;and human microsomes. ;[902..908]:quantitative-value:"> 2000" ;[910..923]:quantitative-units:"micrograms/ml" ;[945..951]:cyp450:"CYP2E1" (SENT (S (NP-SBJ (ADJP (FW:[827..829] In) (FW:[830..835] vitro)) (NNS:[837..848] experiments)) (VP (VBN:[849..854] shown) (SBAR (IN:[855..859] that) (S (NP-SBJ (NP (DT:[860..864] both) (NNS:[865..877] preparations)) (PP (IN:[878..880] at) (NP (JJ:[881..885] high) (NNS:[886..900] concentrations) (PRN (-LRB-:[901..902] -LRB-) (ADJP (SYM:[902..903] >) (NP (NP (CD:[904..908] 2000) (NNS:[910..920] micrograms)) (PP (SYM:[920..921] /) (NP (NN:[921..923] ml))))) (-RRB-:[923..924] -RRB-))))) (VP (VBP:[925..928] are) (ADJP-PRD (JJ:[929..933] able) (S (NP-SBJ (-NONE-:[933..933] *)) (VP (TO:[934..936] to) (VP (VB:[937..944] inhibit) (NP (NN:[945..951] CYP2E1) (JJ:[952..961] enzymatic) (NN:[962..970] activity)) (PP-LOC (IN:[971..973] in) (NP (NP (NN:[974..979] mouse) (NML-1 (-NONE-:[979..979] *P*))) (CC:[980..983] and) (NP (JJ:[984..989] human) (NML-1 (NNS:[991..1001] microsomes))))))))))))) (.:[1001..1002] .))) ;sentence 8 Span:1003..1182 ;However, we did not observe any modification of Cyp2e1 gene expression ;(enzymatic activity, protein and mRNA levels) in mice treated with either ;crude extract or total saponins. ;[1096..1103]:cyp450:"protein" ;[1108..1112]:substance:"mRNA" ;[1150..1163]:substance:"crude extract" ;[1173..1181]:substance:"saponins" (SENT (S (ADVP (RB:[1003..1010] However)) (,:[1010..1011] ,) (NP-SBJ (PRP:[1012..1014] we)) (VP (VBD:[1015..1018] did) (RB:[1019..1022] not) (VP (VB:[1023..1030] observe) (NP (NP (DT:[1031..1034] any) (NN:[1035..1047] modification)) (PP (IN:[1048..1050] of) (NP (NN:[1051..1057] Cyp2e1) (NN:[1058..1062] gene) (NN:[1064..1074] expression))) (PRN (-LRB-:[1075..1076] -LRB-) (NP (NP (JJ:[1076..1085] enzymatic) (NN:[1086..1094] activity)) (,:[1094..1095] ,) (NP (NP (NN:[1096..1103] protein) (NML-1 (-NONE-:[1103..1103] *P*))) (CC:[1104..1107] and) (NP (NN:[1108..1112] mRNA) (NML-1 (NNS:[1113..1119] levels))))) (-RRB-:[1119..1120] -RRB-))) (PP-LOC (IN:[1121..1123] in) (NP (NP (NNS:[1124..1128] mice)) (VP (VBN:[1129..1136] treated) (NP (-NONE-:[1136..1136] *)) (PP-MNR (IN:[1137..1141] with) (NP (CC:[1143..1149] either) (NP (JJ:[1150..1155] crude) (NN:[1156..1163] extract)) (CC:[1164..1166] or) (NP (JJ:[1167..1172] total) (NNS:[1173..1181] saponins))))))))) (.:[1181..1182] .))) ;sentence 9 Span:1183..1285 ;Taken together, these data demonstrated that Panax vietnamensis could be ;used as an hepatoprotectant. ;[1229..1247]:substance:"Panax vietnamensis" ;[1268..1284]:substance:"hepatoprotectant" (SENT (S (S-MNR (NP-SBJ (-NONE-:[1183..1183] *)) (VP (VBN:[1183..1188] Taken) (ADVP (RB:[1189..1197] together)))) (,:[1197..1198] ,) (NP-SBJ (DT:[1199..1204] these) (NNS:[1205..1209] data)) (VP (VBD:[1210..1222] demonstrated) (SBAR (IN:[1224..1228] that) (S (NP-SBJ-1 (NN:[1229..1234] Panax) (NN:[1235..1247] vietnamensis)) (VP (MD:[1248..1253] could) (VP (VB:[1254..1256] be) (VP (VBN:[1257..1261] used) (NP-1 (-NONE-:[1261..1261] *)) (PP-MNR (IN:[1262..1264] as) (NP (DT:[1265..1267] an) (NN:[1268..1284] hepatoprotectant))))))))) (.:[1284..1285] .))) ;sentence 10 Span:1286..1441 ;However, the mechanism of action is not associated with CYP2E1 expression, ;as previously suggested in vitro in rat for total saponins from Panax ;ginseng. ;[1343..1349]:cyp450:"CYP2E1" ;[1413..1421]:substance:"saponins" ;[1427..1440]:substance:"Panax ginseng" (SENT (S (ADVP (RB:[1286..1293] However)) (,:[1293..1294] ,) (NP-SBJ-1 (NP (DT:[1295..1298] the) (NN:[1300..1309] mechanism)) (PP (IN:[1310..1312] of) (NP (NN:[1313..1319] action)))) (VP (VBZ:[1320..1322] is) (RB:[1323..1326] not) (VP (VBN:[1327..1337] associated) (NP-1 (-NONE-:[1337..1337] *)) (PP-CLR (IN:[1338..1342] with) (NP (NN:[1343..1349] CYP2E1) (NN:[1350..1360] expression))) (,:[1360..1361] ,) (PP (IN:[1362..1364] as) (S-NOM (NP-SBJ-2 (-NONE-:[1364..1364] *)) (ADVP (RB:[1365..1375] previously)) (VP (VBN:[1377..1386] suggested) (NP-2 (-NONE-:[1386..1386] *)) (ADVP (FW:[1387..1389] in) (FW:[1390..1395] vitro)) (PP-LOC (IN:[1396..1398] in) (NP (NN:[1399..1402] rat))) (PP (IN:[1403..1406] for) (NP (NP (JJ:[1407..1412] total) (NNS:[1413..1421] saponins)) (PP (IN:[1422..1426] from) (NP (NN:[1427..1432] Panax) (NN:[1433..1440] ginseng)))))))))) (.:[1440..1441] .))) ;section 11 Span:1445..1490 ;PMID: 11199127 [PubMed - indexed for MEDLINE] (SEC (FRAG (NNP:[1445..1449] PMID) (::[1449..1450] :) (CD:[1451..1459] 11199127) (NN:[1460..1461] -LSB-) (NNP:[1461..1467] PubMed) (::[1468..1469] -) (NN:[1470..1477] indexed) (IN:[1478..1481] for) (NNP:[1482..1490] MEDLINE-RSB-)))